• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 17th December 2014

EQ-VAS an Important and Under-used Element of the EQ-5D

On 18th November 2014 OHE’s Professor Nancy Devlin presented at the King’s Fund Patient-reported outcome measures (PROMs) research conference. Nancy’s presentation focused on the role of the EQ-VAS. On 18th November 2014 OHE’s Professor Nancy Devlin presented at the King’s…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

On 18th November 2014 OHE’s Professor Nancy Devlin presented at the King’s Fund Patient-reported outcome measures (PROMs) research conference. Nancy’s presentation focused on the role of the EQ-VAS.

On 18th November 2014 OHE’s Professor Nancy Devlin presented at the King’s Fund Patient-reported outcome measures (PROMs) research conference. Nancy’s presentation focused on the role of the EQ-VAS.
 

Devlin proms conference_ 18 nov 14 from Office of Health Economics
 
The presentation draws on results from a study recently published in Quality of Life Research, with co-authors Dr Yan Feng from OHE and Professor David Parkin from King’s College, London [1].
 
The EQ-5D, used to collect the PROMs data, has two parts. The first, the EQ-5D profile, asks patients to classify their health based on self-assessed levels of problems (“no”, “some”, “extreme”) on five dimensions. The second is the EQ-VAS, which asks patients to indicate their overall health on a vertical visual analogue scale, ranging from “worst possible” to “best possible” health. Historically, the EQ-VAS was a warm-up exercise for VAS valuations of EQ-5D, but it has evolved into an integral part of the measure.
 
In her presentation, Nancy explained the background of visual analogue scales in psychophysics; the properties of the EQ-VAS included in the EQ-5D, and characteristics of the EQ-VAS data in the PROMs programme. 
 
Important points noted include:
 
– There is a systematic relationship between patients’ EQ-5D profile data and their self-reported EQ-VAS
– The EQ-VAS provides important, complementary information on patients’ views about  their own health
– EQ-VAS measures something which is conceptually different than the EQ-5D profile, 
– Where patients’ views are paramount, the EQ-VAS arguably has some important advantages over the EQ Index as a way of summarising patient health. 
 
While some concerns about coding EQ-VAS data had arisen in the context of the NHS PROMs programme, it was noted that 85% of patients completed the EQ-VAS in a clear and unambiguous manner. However, improvements in the instructions about completing the EQ-VAS are required, as is research on the way respondents interpret the endpoints of the scale. 
 
For additional information, please contact Nancy Devlin.
 
[1] Feng, Y., Parkin, D. and Devlin, N.J., 2013. Assessing the performance of the EQ-VAS in the NHS PROMs Programme. Quality of Life Research. Epub ahead of print. 1 October. 
 
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Presentations

Related News

  • News
  • March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Read more
  • News
  • March 2020

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Read more
  • News
  • January 2020

Funding Challenges in the Malaysian Health Care System

Read more
  • News
  • January 2020

OHE at HESG Winter 2020

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!